ADMA Biologics, Inc. revised financial guidance for the years 2024 and 2025. For the years 2024 and 2025, the company expects total revenue now to be more than $330 million and $380 million, respectively, increased from prior guidance of $320 million and $370 million, respectively.
Market Closed -
Other stock markets
|
Pre-market 07:58:53 am | |||
6.655 USD | +2.07% | 6.635 | -0.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.23% | 1.55B | |
-3.93% | 86.16B | |
+2.76% | 40.17B | |
-16.48% | 31.47B | |
+54.69% | 25.24B | |
-13.58% | 15.82B | |
-9.12% | 11.96B | |
-42.56% | 11.61B | |
+4.87% | 8.84B | |
-2.11% | 7.93B |
- Stock Market
- Equities
- ADMA Stock
- News ADMA Biologics, Inc.
- ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025